Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

MATURE RESULTS FROM A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN PLUS ADRIAMYCIN AND DACARBAZINE WITHOUT RADIATION IN NON‐BULKY LIMITED STAGE CLASSICAL HODGKIN LYMPHOMA.

Autor: Abramson, J. S., Bengston, E. M., Redd, R., Barnes, J. A., Takvorian, T., Sokol, L., Lansigan, F., Armand, P., Shah, B., Jacobsen, E., Martignetti, R., Turba, E., Metzler, S. R., Patterson, V., LaCasce, A. S., Bello, C. M.

Publikováno v: Hematological Oncology; Jun2021 Supplement S2, Vol. 39, p1-1, 1p

Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation.

Autor: Kumar A; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Soumerai JD; Massachusetts General Hospital Cancer Center: Hematology Oncology, Boston, Massachusetts, United States., Abramson JS; Mass General Cancer Center, Boston, Massachusetts, United States., Barnes JA; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States., Caron PC; Memorial Sloan Kettering Cancer Center, West Harrison, New York, United States., Chhabra S; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Chabowska M; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Dogan A; Memorial Sloan-Kettering Cancer Center, New York, New York, United States., Falchi L; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Grieve C; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Haydu JE; Mass General Cancer Center, Boston, Massachusetts, United States., Johnson PC; Massachusetts General Hospital / Harvard Medical School, Boston, Massachusetts, Massachusetts, United States., Joseph A; Memorial Sloan-Kettering Cancer Center, New York, New York, United States., Kelly H; Massachusetts General Hospital Cancer Center: Hematology Oncology, Boston, Massachusetts, United States., Labarre A; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Lue JK; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Martignetti R; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States., Mi J; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Moskowitz AJ; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Owens CN; Memorial Sloan Kettering Cancer Center, Middletown, New Jersey, United States., Plummer S; Massachusetts General Hospital Cancer Center: Hematology Oncology, Boston, Massachusetts, United States., Puccio M; Massachusetts General Hospital Cancer Center: Hematology Oncology, Boston, Massachusetts, United States., Salles GA; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Seshan VE; MSKCC, New York, New York, United States., Simkins E; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States., Slupe N; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Zhang H; Memorial Sloan Kettering Cancer Center, New York, New York, United States., Zelenetz AD; Memorial Sloan Kettering Cancer Center, New York, New York, United States.

Publikováno v: Blood [Blood] 2024 Oct 22. Date of Electronic Publication: 2024 Oct 22.